NIVI Development will facilitate the translational efforts of NIVI by providing industry-level expertise in vaccine development and conducting the early clinical testing of our vaccine candidates.
Bridging research, translational sciences, and development
NIVI Development will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NIVI Development provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.NIVI
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
Bridging research, translational sciences, and development
We are a part of NIVI
– the Novo Nordisk Foundation Initiative for Vaccines and Immunity
NIVI Development P/S
Ørestads Boulevard 5
2300 København S
© NIVI Development